A new vaccine vanquishes meningitis A in Africa

See allHide authors and affiliations

Science  12 Sep 2014:
Vol. 345, Issue 6202, pp. 1265
DOI: 10.1126/science.345.6202.1265


Every few years with the onset of the dry season, Neisseria meningitidis sweeps across a swath of Africa, causing bacterial meningitis that kills 5% to 10% of those infected and leaves many others deaf or disabled. No good affordable vaccine existed for the main strain in Africa, serotype A. In the early 2000s, a public-private partnership called the Meningitis Vaccine Project set out to develop the first vaccine specifically for Africa at a price Africans can afford—less than 50 cents a dose. It has been called one of the most dramatic successes in global health. Meningitis cases have dropped to near zero in every country where MenAfriVac has been introduced since 2010.

View Full Text

Stay Connected to Science